Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells

Oxid Med Cell Longev. 2014:2014:906804. doi: 10.1155/2014/906804. Epub 2014 May 8.

Abstract

Piperlongumine (PL), a natural alkaloid from Piper longum L., possesses the highly selective and effective anticancer property. However, the effect of PL on ovarian cancer cells is still unknown. In this study, we firstly demonstrate that PL selectively inhibited cell growth of human ovarian cancer cells. Furthermore, PL notably induced cell apoptosis, G2/M phase arrest, and accumulation of the intracellular reactive oxidative species (ROS) in a dose- and time-dependent manner. Pretreatment with antioxidant N-acety-L-cysteine could totally reverse the PL-induced ROS accumulation and cell apoptosis. In addition, low dose of PL/cisplatin or paclitaxel combination therapies had a synergistic antigrowth effect on human ovarian cancer cells. Collectively, our study provides new therapeutic potential of PL on human ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / pharmacology
  • Apoptosis / drug effects*
  • Cell Line, Tumor
  • Cisplatin / pharmacology*
  • Dioxolanes / pharmacology*
  • Drug Synergism
  • Female
  • G2 Phase Cell Cycle Checkpoints / drug effects
  • Humans
  • M Phase Cell Cycle Checkpoints / drug effects
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology
  • Paclitaxel / pharmacology*
  • Reactive Oxygen Species / metabolism

Substances

  • Dioxolanes
  • Reactive Oxygen Species
  • piperlongumine
  • Paclitaxel
  • Cisplatin
  • Acetylcysteine